Mohammad Hirmand Turning Point Therapeutics, Inc. (TPTX) insider trading activity

Mohammad Hirmand is EVP and Chief Medical Officer of Turning Point Therapeutics, Inc.. Currently has a direct ownership of 0 shares of TPTX, which is worth approximately $0. The most recent transaction as insider was on Aug 17, 2022, when has been sold 41,284 shares (Common Stock) at a price of $76.0 per share, resulting in proceeds of $3,137,584. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Mohammad Hirmand Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 17 2022	SELL Sale (or disposition) back to the issuer	$3,137,584 $76.0 p/Share	41,284 Reduced 100.0%	0 Common Stock
Feb 09 2022	SELL Open market or private sale	$24,285 $36.3 p/Share	669 Reduced 8.91%	6,838 Common Stock
Feb 09 2022	BUY Grant, award, or other acquisition	-	33,983 Added 45.43%	40,821 Common Stock
Feb 08 2021	BUY Grant, award, or other acquisition	-	6,483 Added 48.93%	6,767 Common Stock
Jan 05 2021	SELL Open market or private sale	$150,360 $120.0 p/Share	1,253 Reduced 81.52%	284 Common Stock
Jan 05 2021	BUY Exercise of conversion of derivative security	$68,577 $54.73 p/Share	1,253 Added 44.91%	1,537 Common Stock
Jan 04 2021	SELL Open market or private sale	$1,098,577 $121.43 p/Share	9,047 Reduced 96.96%	284 Common Stock
Jan 04 2021	BUY Exercise of conversion of derivative security	$478,723 $54.73 p/Share	8,747 Added 48.38%	9,331 Common Stock

Also insider at

AADI

Aadi Bioscience, Inc. Healthcare